Pressmeddelanden, rapporter och bolagsmeddelande för Cessatech

The general meeting elected Mikkel Rostock-Jensen as chairman, who confirmed the meeting's legality and noted strong support for all agenda proposals. The meeting reviewed the company's activities for 2024 and unanimously adopted the audited annual report. It resolved to carry forward a loss of tDKK 19,053 to the next financial year. Martin Olin, Charlotte Videbæk, Flemming Steen Jensen, and Rachel Curtis Gravesen were re-elected to the board, with Martin Olin as chairman. PricewaterhouseCoopers was re-elected as auditor. No proposals from the board or shareholders were presented, and the meeting concluded.

Cessatech A/S has scheduled its annual general meeting for March 28, 2025, at its Hellerup address. The agenda includes the election of a meeting chairman, a report on company activities, the adoption of the 2024 annual report, a resolution on handling financial losses, board and auditor elections, and proposals from the board and shareholders. Mikkel Rostock-Jensen is proposed as chairman, and the board suggests re-electing PricewaterhouseCoopers as auditor. Shareholders can vote by proxy or mail, with submissions due by March 27, 2025. Documents related to the meeting are available on the company's website. Shareholders must register by March 21, 2025, to vote and can request admission cards via email. They can also participate online, with the option to ask questions during the meeting.

Under 2024 rapporterade Cessatech ett nettointäktsbelopp på KDKK 2.486 och ett rörelseresultat på KDKK -19.053. Nettoresultatet var KDKK -14.670. Vid periodens slut uppgick banktillgångarna till KDKK 12.373. Resultat per aktie var KDKK -0,85 och soliditeten var 52%. Årsredovisningen kommer att presenteras för godkännande vid årsstämman den 28 mars 2025, där styrelsen och VD har föreslagit att ingen utdelning betalas ut för räkenskapsåret 2024. Under året genomfördes en framgångsrik TO2-teckningsoption med 94,7% utnyttjande, vilket gav cirka DKK 17,1 miljoner i bruttoproveny. En pediatrisk studie (0202) initierades och visade lovande resultat för smärtlindring med CT001. Låneavtalet med investerare ökades till DKK 10 miljoner och förlängdes till april 2026. Vid årets slut hade patientrekryteringen i studien nått halvvägs, med 75 patienter inkluderade.

Cessatech A/S announced that it received a positive opinion from a Notified Body under the EU Medical Devices Regulation for its product CT001. The technical documentation for CT001 was deemed adequate to meet safety and performance requirements. This opinion is part of the EMA approval process and indicates that the product meets EU standards for safety and efficacy. Cessatech's CSO, Martin Juhl, expressed pride in the team's efforts and highlighted the innovative use of the Interactive Online Review Process. CEO Jes Trygved noted that this achievement brings the company closer to getting CT001 approved in Europe for children aged 1-17, in collaboration with commercial partner Proveca. The MDR process has seen over 3,000 certificates and opinions completed since 2021, despite a significant backlog.